USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Gemvax & KAEL Co., Ltd.

USPTO PatentsView assignee record - 41 granted patents across 11 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

12.0

Avg claims per patent

+28%

5-year grant velocity

The verdict

According to USPTO PatentsView, Gemvax ranks #7,850 of 50,000 tracked US assignees by granted-patent volume, with 41 patents across 11 technology areas.

#7,850
of 50,000 US assignees by volume: Top 48%
by Innovation Score (35.8/100): 12.0
avg claims per patent: +28%
grant velocity, last 5 yrs

Portfolio overview

Gemvax & KAEL Co., Ltd. has been granted 41 US utility patents between 2016 and 2024, placing Gemvax & KAEL Co., Ltd. at #7,850 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.0 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Gemvax & KAEL Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Gemvax sits between General Plastic Industrial Co., Ltd. (41 patents, rank #7,848) and Hospices Civils DE LYON (41 patents, rank #7,856) - the closest US assignees by grant volume. The composite Innovation Score of 35.8/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 23 grants, compared with 18 in the 2015–2019 window, a +28% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Gemvax & KAEL Co., Ltd.'s 12.0 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 11 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

General Plastic I…

41
Gurulogic Microsy…

41
Game Play Network

41
Garland Industries

41
HALO Internationa…

41
Hamilton Sundstra…

41
Hefei BOE Display…

41
Hospices Civils D…

41
Gemvax & KAEL ◀

41

What this shows Gemvax holds 41 patents at rank #7,852, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Gemvax

By rank, the assignees closest to #7,852 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Gemvax's primary technology class.

Gemvax's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 48% higher than 52% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Gemvax & KAEL Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	2.4%
2017	7	17.1%
2018	6	14.6%
2019	4	9.8%
2020	5	12.2%
2021	8	19.5%
2022	1	2.4%
2023	4	9.8%
2024	5	12.2%

Which technologies does Gemvax & KAEL Co., Ltd. patent most?

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 40

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 37

C07K - PEPTIDES 29

A23L - FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF 29

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 29

C12Y - ENZYMES 28

A23V - INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION 28

A61Q - SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS 17

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 14

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 4

A01N - PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS 1

Top 11 of 11 technology areas

Grant record at a glance

Portfolio Volume 41 grants

CPC subclasses 11

Avg. claims / grant 12.0

Velocity +28%

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#7,850

of 50,000 tracked assignees

Innovation Score

35.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Gemvax & KAEL Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Gemvax & KAEL Co., Ltd. ranks #7,850 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Gemvax & KAEL Co., Ltd. hold?

Gemvax & KAEL Co., Ltd. holds 41 US utility patents granted between 2016 and 2024, spanning 11 technology areas.

What is Gemvax & KAEL Co., Ltd.'s Innovation Score?

Gemvax & KAEL Co., Ltd. has an Innovation Score of 35.8 out of 100 (top 48% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Gemvax & KAEL Co., Ltd. focus on?

Gemvax & KAEL Co., Ltd.'s top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 40 patents. Grants appear in 11 CPC subclasses total.

Is Gemvax & KAEL Co., Ltd.'s patent grant rate increasing or decreasing?

Gemvax & KAEL Co., Ltd.'s recent grant velocity is +28% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Gemvax & KAEL Co., Ltd.'s patents?

Gemvax & KAEL Co., Ltd.'s patents average 12.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Gemvax & KAEL Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Gemvax's 41 grants land it in the top 48% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Gemvax ranks #7,850 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.